Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Invest New Drugs. 2018 Aug;36(4):601-607. doi: 10.1007/s10637-017-0524-2. Epub 2017 Oct 27.
We present the first reported work that explores the potential of radiomics to predict patients who are at risk for developing immunotherapy-induced pneumonitis. Despite promising results with immunotherapies, immune-related adverse events (irAEs) are challenging. Although less common, pneumonitis is a potentially fatal irAE. Thus, early detection is critical for improving treatment outcomes; an urgent need to identify biomarkers that predict patients at risk for pneumonitis exists. Radiomics, an emerging field, is the automated extraction of high fidelity, high-dimensional imaging features from standard medical images and allows for comprehensive visualization and characterization of the tissue of interest and corresponding microenvironment. In this pilot study, we sought to determine whether radiomics has the potential to predict development of pneumonitis. We performed radiomic analyses using baseline chest computed tomography images of patients who did (N = 2) and did not (N = 30) develop immunotherapy-induced pneumonitis. We extracted 1860 radiomic features in each patient. Maximum relevance and minimum redundancy feature selection method, anomaly detection algorithm, and leave-one-out cross-validation identified radiomic features that were significantly different and predicted subsequent immunotherapy-induced pneumonitis (accuracy, 100% [p = 0.0033]). This study suggests that radiomic features can classify and predict those patients at baseline who will subsequently develop immunotherapy-induced pneumonitis, further enabling risk-stratification that will ultimately lead to better treatment outcomes.
我们首次报告了一项探索放射组学预测发生免疫治疗相关肺炎风险患者的潜力的工作。尽管免疫疗法有很好的疗效,但免疫相关不良事件(irAE)是一个挑战。虽然不太常见,但肺炎是一种潜在的致命性 irAE。因此,早期检测对于改善治疗结果至关重要;迫切需要确定预测肺炎风险的生物标志物。放射组学是一个新兴领域,它可以从标准医学图像中自动提取高保真度、高维的成像特征,并允许对感兴趣的组织及其相应的微环境进行全面的可视化和特征描述。在这项初步研究中,我们试图确定放射组学是否有潜力预测肺炎的发生。我们对发生(N=2)和未发生(N=30)免疫治疗相关肺炎的患者的基线胸部 CT 图像进行了放射组学分析。我们在每位患者中提取了 1860 个放射组学特征。最大相关性和最小冗余特征选择方法、异常检测算法和留一交叉验证确定了显著不同且预测随后发生免疫治疗相关肺炎的放射组学特征(准确率为 100%[p=0.0033])。这项研究表明,放射组学特征可以对那些随后会发生免疫治疗相关肺炎的患者进行分类和预测,进一步实现风险分层,最终导致更好的治疗结果。